Results 21 to 30 of about 48,562 (198)
Janus Kinase Inhibitors: Safety in Patients With Psoriatic Arthritis
, 2022 Janus kinase inhibitors (JAKi; or Jakinibs) have become widely prescribed around the world for a variety of immune-mediated inflammatory diseases, including psoriatic arthritis.
Nash, P
core +1 more source
Acta Dermato-Venereologica, 2022 The aim of this study was to compare the efficacies of systemic treatments with dupilumab, tralokinumab and Janus kinase inhibitors for moderate-to-severe atopic dermatitis. A systematic review following Preferred Reporting Items for Systemic Reviews and
Farnam B. Sedeh +3 more
doaj +1 more source
Janus Kinase Inhibitors in the Treatment of Alopecia Areata
Prague Medical Report, 2023 Alopecia areata is a disease of autoimmune origin which causes non scarring hair loss. The extent of alopecia varies from a small patch to complete scalp and body hair loss, which can have huge psychosocial impact for those affected. Treatment modalities
Athanasios J. Stefanis
doaj +1 more source
Janus kinase inhibitors in autoimmune diseases [PDF]
Annals of the Rheumatic Diseases, 2013 Biological therapies directed at proinflammatory cytokines have irrevocably changed the landscape of treatment of rheumatoid arthritis (RA) and other autoimmune diseases. With the advances in our knowledge in cytokine signalling, the question emerges whether targeting intracellular signalling might also be a safe and efficacious strategy. Janus kinases
John J, O'Shea +4 more
openaire +2 more sources
A JAK of all trades: how global phosphoproteomics reveal the Achilles heel of MPNs
Molecular & Cellular Oncology, 2021 While Janus-kinase (JAK)-inhibitors effectively reduce the inflammatory phenotype of myeloproliferative neoplasms (MPN), they do not affect disease burden or presence of the mutated clone to a major extent. Here, we show how Janus-kinase 2 (JAK2)-mutated
Tina M. Schnoeder +2 more
doaj +1 more source
Ruxolitinib found to cause eyelash growth: a case report
Journal of Medical Case Reports, 2017 Background Hypereosinophilic syndrome is a hematologic disorder in which the eosinophils proliferate. Oral Janus kinase inhibitors are known to be effective treating hypereosinophilic syndrome.
Julia Song +4 more
doaj +1 more source
The Emerging World of JAK Inhibitors
Nepal Journal of Dermatology, Venereology & LeprologyThe Janus Kinase inhibitors are a new emerging class of small molecules. These target the Janus Kinase proteins located on the cell membrane. Janus Kinase proteins regulate the cellular transcription of several proteins and act as mediators in several ...
Shraddha Uprety
doaj +3 more sources
, 2023 This retrospective cohort study aims to compare the risk of three-point major adverse events, malignancy, and serious infection between Janus kinase inhibitors and tumor necrosis factor inhibitors by using nationwide claims data of ...
Dongwon Yoon +4 more
core +1 more source
Clinical-economic analysis of the target therapy in severe atopic dermatitidis in adults
Качественная клиническая практика, 2022 Target therapy of severe atopic dermatitidis (AD) is actual because AD has a high prevalence and social-economic burden. Target therapy consists of monoclonal antibodies (dupilumab) as well as janus kinase inhibitors (upadacitinib and baricitinib).
A. S. Kolbin +3 more
doaj +1 more source
BMC Infectious Diseases, 2021 Background The spread of a highly pathogenic, novel coronavirus (SARS-CoV-2) has emerged as a once-in-a-century pandemic, having already infected over 63 million people worldwide. Novel therapies are urgently needed.
Lucas Walz +6 more
doaj +1 more source